The trial enrolled 329 Chinese adult patients with diabesity who exhibited representative real-world metabolic characteristics: Mean age: approximately 42 years Mean HbA1c: 8.02% Mean BMI: 33.0 kg/m Mean body weight: 90.5 kg Mean disease duration: 1.8 years Participants were randomized 1:1 to receive: Mazdutide (69 mg dose escalation) Semaglutide (1 mg standard treatment regimen) The treatment duration was 32 weeks, with evaluation of both glycemic and weight-related metabolic endpoints
**Room temperature storage (acceptable):** The prescribing information permits storage below 86F (30C) for up to 56 days
PlexusDx does not sell, prescribe, or recommend any therapeutic peptide outside the GLP-1 category covered by its protocols
The most commonly reported adverse events across all treatment arms were gastrointestinal-related, including nausea (17.4 percent [5 mg], 19.2 percent [10 mg], 22.1 percent [15 mg], 17.9 percent [semaglutide]), diarrhea (13.2 percent [5 mg], 16.4 percent [10 mg], 13.8 percent [15 mg], 11.5 percent [semaglutide]) and vomiting (5.7 percent [5 mg], 8.5 percent [10 mg], 9.8 percent [15 mg], 8.3 percent [semaglutide])
Side effect quitters: promising candidates You stopped semaglutide because of intolerable side effects, usually nausea, vomiting, or severe gastrointestinal distress
